Clinical value of preoperative CA19-9 levels in evaluating resectability of gallbladder carcinoma.
This study evaluated the predictive ability of preoperative carbohydrate antigen 19-9 (CA19-9) level in assessing tumour resectability in patients with gallbladder carcinoma (GBC). We retrospectively analysed preoperative serum levels of CA19-9 in 292 patients with potentially resectable GBC between January 2000 and March 2016 in our institution. All final diagnoses were confirmed by pathological examination. The optimal cut-off point of the CA19-9 for predicting resectability was determined by the receiver operating characteristic curve. The univariate analysis and multivariate Cox regression model were applied to assess the relationship between the parameters to resectability. A total of 292 patients with surgical treatment were included, of whom 195 were identified as curative resection (R0 resection), 69 were classified as R1/2 resection and the remaining 28 patients were operated on with palliative surgery. The receiver operating characteristic curve analysis calculated the best CA19-9 cut-off point of 98.91 U/mL in the prediction of resectability. Meanwhile, the sensitivity, specificity, positive predictive value and negative predictive value were 76.3%, 70.8%, 85.7% and 56.5%, respectively. In the multivariate logistic regression analysis, CA19-9 >98.91 U/mL (odds ratio (OR) 6.339, 95% confidence interval (CI) 3.562-11.284, P < 0.001), tumour located on hepatic side (OR 1.787, 95% CI 1.022-3.123, P = 0.042) and advanced American Joint Committee on Cancer stage (OR 2.156, 95% CI 1.180-3.940, P = 0.013) were independent determinants of resectability in patients diagnosed as GBC. Preoperative CA19-9 predicts resectability in patients with radiological resectable GBC. Increased preoperative CA19-9 is related to poor resectability rate.